Biomarkers Enhance Discrimination and Prognosis of Type 2 Myocardial Infarction | Zendy

Yu Horiuchi | Zendy; Nicholas Wettersten | Zendy; Mitul Patel | Zendy; Christian Mueller | Zendy; SeanXavier Neath | Zendy; Robert H. Christenson | Zendy; Nils G. Morgenthaler | Zendy; James McCord | Zendy; Richard M. Nowak | Zendy; Gary M. Vilke | Zendy; Lori B. Daniels | Zendy; Judd E. Hollander | Zendy; Fred S. Apple | Zendy; Chad Can | Zendy; John Tobias Nagurney | Zendy; Donald Schreiber | Zendy; Christopher R. deFilippi | Zendy; Christopher J. Hogan | Zendy; Deborah B. Diercks | Zendy; Gary Headden | Zendy; Alexander T. Limkakeng | Zendy; Inder S. Anand | Zendy; Alan H.B. Wu | Zendy; Stefan Ebmeyer | Zendy; Allan S. Jaffe | Zendy; W. Frank Peacock | Zendy; Alan Maisel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Biomarkers Enhance Discrimination and Prognosis of Type 2 Myocardial Infarction

Author(s) -

Yu Horiuchi,

Nicholas Wettersten,

Mitul Patel,

Christian Mueller,

SeanXavier Neath,

Robert H. Christenson,

Nils G. Morgenthaler,

James McCord,

Richard M. Nowak,

Gary M. Vilke,

Lori B. Daniels,

Judd E. Hollander,

Fred S. Apple,

Chad Can,

John Tobias Nagurney,

Donald Schreiber,

Christopher R. deFilippi,

Christopher J. Hogan,

Deborah B. Diercks,

Gary Headden,

Alexander T. Limkakeng,

Inder S. Anand,

Alan H.B. Wu,

Stefan Ebmeyer,

Allan S. Jaffe,

W. Frank Peacock,

Alan Maisel

Publication year - 2020

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.120.046682

Subject(s) - medicine , copeptin , myocardial infarction , cardiology , unstable angina , heart failure , emergency department , procalcitonin , receiver operating characteristic , natriuretic peptide , biomarker , troponin i , sepsis , biochemistry , chemistry , psychiatry , vasopressin

The observed incidence of type 2 myocardial infarction (T2MI) is expected to increase with the implementation of increasingly sensitive cTn assays. However, it remains to be determined how to diagnose, risk-stratify, and treat patients with T2MI. We aimed to discriminate and risk-stratify T2MI using biomarkers.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research